


IN THE CLAIMS

1-41 (canceled)

42. (new) A compound of formula 1,

1

wherein

n is 1 or 2, and

 $R^1$ 

(i) is  $-C_{1-10}$ -alkyl, which is straight-chain or branched and optionally substituted, once or more than once, by mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated carbocycles having 3-14 ring members, where the carbocyclic substituents are substituted once or more than once by  $-NO_2$  be optionally substituted, once or more than once, by  $-C_{1-6}$ -alkyl,  $-OH$ ,  $-NH_2$ ,  $-NHC_{1-6}$ -alkyl,  $-N(C_{1-6}\text{-alkyl})_2$ ,  $-NO_2$ ,  $-CN$ ,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O-C_{1-6}$ -alkyl,  $-S-C_{1-6}$ -alkyl,  $-SO_3H$ ,  $-SO_2C_{1-6}$ -alkyl,  $-OSO_2C_{1-6}$ alkyl,  $-COOH$ ,  $-(CO)C_{1-5}$ -alkyl or  $-O(CO)C_{1-5}$ -alkyl, and where the alkyl groups on the carbocyclic substituents can, for their part, be

optionally substituted, once or more than once, by -OH, -SH, -NH<sub>2</sub>, -F, -Cl, -Br, -I, -SO<sub>3</sub>H or -COOH;

R<sup>2</sup> and R<sup>3</sup>

(i) are, in each case independently of each other, hydrogen or -C<sub>1-5</sub>-alkyl,

which is optionally substituted, once or more than once, by -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub>-alkyl, -N(C<sub>1-6</sub>-alkyl)<sub>2</sub>, -NO<sub>2</sub>, -CN, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub>-alkyl, -S-C<sub>1-6</sub>-alkyl, -phenyl or -pyridyl,

-phenyl,

which is optionally substituted, once or more than once, by -C<sub>1-3</sub>-alkyl, -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-3</sub>-alkyl, -N(C<sub>1-3</sub>-alkyl)<sub>2</sub>, -NO<sub>2</sub>, -CN, -COOH, -COOC<sub>1-3</sub>-alkyl, -F, -Cl, -Br, -I, -O-C<sub>1-3</sub>-alkyl, -S-C<sub>1-3</sub>-alkyl or -O(CO)-C<sub>1-3</sub>-alkyl,

-pyridyl,

which is optionally substituted, once or more than once, by -C<sub>1-3</sub>-alkyl, -OH, -SH, -NO<sub>2</sub>, -CN, -COOH, -COOC<sub>1-3</sub>-alkyl, -F, -Cl, -Br, -I, -O-C<sub>1-3</sub>-alkyl, -S-C<sub>1-3</sub>-alkyl or -O(CO)-C<sub>1-3</sub>-alkyl,

where only one of R<sup>2</sup> and R<sup>3</sup> is hydrogen and where the alkyl groups on the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by -OH, -SH, -NH<sub>2</sub>, -F, -Cl, -Br, -I, -SO<sub>3</sub>H, -COOH, -O(CO)-C<sub>1-5</sub>-alkyl, or -O(CO)C<sub>1-5</sub>-alkyl, or


(ii) NR<sup>2</sup>R<sup>3</sup> together form a saturated or unsaturated five-membered or six-membered ring which can contain up to 3 heteroatoms, preferably N, S and O, and which is optionally substituted, once or more than once, by -C<sub>1-3</sub>-alkyl, -OH, -SH, -NO<sub>2</sub>, -CN,

-COOH, -COOC<sub>1-3</sub>-alkyl, -F, -Cl, -Br, -I, -O-C<sub>1-3</sub>-alkyl, -S-C<sub>1-3</sub>-alkyl or  
-O(CO)-C<sub>1-3</sub>-alkyl,


R<sup>4</sup> and R<sup>5</sup> are -H or -OH, where at least one of the two must be -OH, or salts of the compounds according to formula 1.

43. (new) A compound according to claim 42, wherein said compound has an asymmetric carbon atom in the D form or L form, or D,L mixtures or, when more than one asymmetrical carbon atom is present, the diastereomeric forms.
44. (new) A compound according to claim 42, wherein n is 2.
45. (new) A compound according to claim 42, wherein R<sup>4</sup> = -OH and R<sup>5</sup> = -H.
46. (new) A compound according to claim 42, wherein -NR<sup>2</sup>R<sup>3</sup> is a phenylamino or pyridylamino which is substituted by one or more halogen atoms.
47. (new) A compound according to claim 42, wherein R<sup>1</sup> is a substituted benzyl radical.
48. (new) A compound according to claim 47, wherein the benzyl radical contains at least one substituent in the ortho position on the phenyl ring.
49. (new) A compound according to claim 42, selected from the group consisting of,  
  
N-(3,5-dichloropyridin-4-yl)-[1-(3-nitrobenzyl)-7-hydroxyindol-3-yl]glyoxylic acid  
amide  
  
and physiologically tolerated salts thereof.

50. (new) A process for preparing a compound according to claim 22, comprising reacting an indole-3-carboxylic acid of formula 2:




with an acid chloride to form the analogous indole-3-carbonyl chloride of the formula 3




reacting the compound of formula 3 with a primary and a secondary amine to form the corresponding amide and eliminating a protecting group to form a compound of formula 1, wherein  $n = 1$ .

51. (new) A process according to claim 50, wherein said acid chloride is thionyl chloride or oxalyl chloride to synthesize the indole-3-carbonyl chlorides according to formula 3.
52. (new) A process according to claim 50, wherein said indole-3-carbonyl chloride according to formula 3 are reacted with primary or secondary amines in the presence of an auxiliary base.
53. (new) A process according to claim 50, wherein said indole-3-carbonyl chloride is reacted with a primary or secondary amine in the presence of an excess of amine.
54. (new) A process according to claim 53, wherein the excess amine is a tertiary amine.
55. (new) A process according to claim 52, wherein indole-3-carbonyl chloride is reacted in the presence of an inorganic base.
56. (new) A process for preparing a compound according to claim 42, comprising reacting an indole formula 4



with oxalyl chloride to form the analogous indol-3-ylglyoxylyl chloride of formula 5



formula 5

reacting the compound of formula 5 with a primary or secondary amine to form the corresponding amide and eliminating a protecting group to form a compound according to formula 1, wherein n is 2.

57. (new) A process according to claim 56, wherein indol-3-ylglyoxylyl chlorides according to formula 5 are reacted with primary or secondary amines in the presence of an auxiliary base.
58. (new) A method for inhibiting PDE 4 comprising administering a sufficient amount of a compound of claim 42 to a subject to inhibit PDE 4.
59. (new) A method for treating a disease associated with the activity of eosinophils, comprising administering a therapeutically effective amount of a compound according to claim 42 to a subject in need thereof.

60. (new) A method for treating a disease associated with the activity of neutrophils comprising administering a therapeutically effective amount of a compound according to claim 42 to a subject in need thereof.
61. (new) A pharmaceutical dosage form comprising at least one compound according to claim 47 and at least one of a customary, physiologically tolerated excipient, diluent or auxiliary substance.
62. (new) A process for producing a pharmaceutical dosage form comprising admixing at least one compound according to claim 42 with a customary pharmaceutical carrier substance, a diluent or an auxiliary substance to form a therapeutically desirable pharmaceutical preparation.
63. (new) A method of treating modifying the activity of PDE 4 in a subject in need thereof comprising administering the dosage form of claim 61 to a subject in need thereof, optionally with a different therapeutically active agent.